Morgan Stanley Acumen Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 153,748 shares of ABOS stock, worth $273,671. This represents 0.0% of its overall portfolio holdings.

Number of Shares

153,748

Previous 152,636 0.73%

Holding current value

$273,671

Previous $167,000 6.59%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$0.9 - $1.27 $1,000 - $1,412	1,112 Added 0.73%	153,748 $178,000
Q1 2025 May 15, 2025	SELL	$1.1 - $1.9 $124,938 - $215,802	-113,580 Reduced 42.66%	152,636 $167,000
Q4 2024 Feb 14, 2025	BUY	$1.72 - $3.27 $46,467 - $88,342	27,016 Added 11.29%	266,216 $457,000
Q3 2024 May 14, 2025	BUY	$2.22 - $3.54 $336,088 - $535,924	151,391 Added 172.41%	239,200 $593,000
Q3 2024 Nov 14, 2024	BUY	$2.22 - $3.54 $336,088 - $535,924	151,391 Added 172.41%	239,200 $593,000
Q2 2024 May 14, 2025	SELL	$2.14 - $4.01 $381,790 - $715,412	-178,407 Reduced 67.02%	87,809 $212,000
Q2 2024 Oct 17, 2024	BUY	$2.14 - $4.01 $83,667 - $156,778	39,097 Added 80.26%	87,809 $212,000
Q2 2024 Aug 14, 2024	BUY	$2.14 - $4.01 $83,667 - $156,778	39,097 Added 80.26%	87,809 $212,000
Q1 2024 Oct 17, 2024	SELL	$2.97 - $4.64 $116,118 - $181,410	-39,097 Reduced 44.53%	48,712 $197,000
Q1 2024 Aug 16, 2024	BUY	$2.97 - $4.64 $75,990 - $118,719	25,586 Added 110.64%	48,712 $197,000
Q1 2024 May 15, 2024	BUY	$2.97 - $4.64 $75,990 - $118,719	25,586 Added 110.64%	48,712 $197,000
Q4 2023 Aug 16, 2024	SELL	$1.86 - $4.48 $120,310 - $289,779	-64,683 Reduced 73.66%	23,126 $88,000
Q4 2023 Feb 13, 2024	BUY	$1.86 - $4.48 $1,649 - $3,973	887 Added 3.99%	23,126 $88,000
Q3 2023 Nov 15, 2023	BUY	$4.15 - $9.72 $28,697 - $67,213	6,915 Added 45.13%	22,239 $92,000
Q2 2023 Aug 14, 2023	SELL	$3.59 - $6.59 $129,900 - $238,452	-36,184 Reduced 70.25%	15,324 $73,000
Q1 2023 May 15, 2023	BUY	$3.75 - $6.65 $96,840 - $171,729	25,824 Added 100.55%	51,508 $209,000
Q4 2022 Feb 14, 2023	BUY	$4.81 - $10.17 $32,563 - $68,850	6,770 Added 35.79%	25,684 $138,000
Q3 2022 Nov 14, 2022	SELL	$4.44 - $10.48 $23,456 - $55,365	-5,283 Reduced 21.83%	18,914 $189,000
Q2 2022 Oct 27, 2022	BUY	$3.08 - $4.88 $32,370 - $51,288	10,510 Added 76.79%	24,197 $114,000
Q2 2022 Aug 15, 2022	BUY	$3.08 - $4.88 $32,370 - $51,288	10,510 Added 76.79%	24,197 $114,000
Q1 2022 Oct 27, 2022	SELL	$3.91 - $6.73 $41,094 - $70,732	-10,510 Reduced 43.44%	13,687 $53,000
Q1 2022 May 13, 2022	SELL	$3.91 - $6.73 $27,158 - $46,746	-6,946 Reduced 33.66%	13,687 $53,000
Q4 2021 Feb 14, 2022	BUY	$6.54 - $15.31 $131,218 - $307,179	20,064 Added 3526.19%	20,633 $139,000
Q3 2021 Nov 15, 2021	BUY	$14.5 - $20.28 $8,250 - $11,539	569 New	569 $8,000

Others Institutions Holding ABOS

# of Institutions

Shares Held

38.8M

Call Options Held

31.5K

Put Options Held

View Full List

About Acumen Pharmaceuticals, Inc.

Ticker ABOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,503,100
Market Cap $72.1M
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...

More about ABOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account